Join to View Full Profile
1500 E Medical Center DrAnn Arbor, MI 48109
Phone+1 734-936-4000
Dr. Campagnaro is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Texas Medical Branch HospitalsResidency, Internal Medicine, 2000 - 2003
Louisiana State University School of Medicine in New OrleansClass of 2000
Certifications & Licensure
MI State Medical License 2007 - 2026
OH State Medical License 2009 - 2019
TX State Medical License 2004 - 2010
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2015-2017
- CMS Meaningful Use Stage Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2015-2017
- CMS Meaningful Use Stage Stage 1 Certification Rhapsody Connect, Orion Health, 2015-2017
Clinical Trials
- Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma Start of enrollment: 2010 Jun 01
- Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
- Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma Start of enrollment: 2010 Jul 01
Publications & Presentations
PubMed
- 1 citationsIsatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702).Terri L Parker, Adam Rosenthal, Vaishali Sanchorawala, Heather J Landau, Erica L Campagnaro
Blood. 2025-11-20 - Management recommendations for kidney transplantation in patients with plasma cell dyscrasia.Naoka Murakami, Christopher D Blosser, Allison B Webber, Gaurav Gupta, Neeraj Singh
Kidney International. 2025-11-01 - 10 citationsNCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson, Muhamed Baljevic
Journal of the National Comprehensive Cancer Network. 2025-05-01
Abstracts/Posters
- Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple MyelomaErica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)Erica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for ImmunotherapyErica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
